OBJECTIVE: Chronic thromboembolic pulmonary hypertension is surgically treated through pulmonary endarterectomy. Although pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension in terms of both functional outcomes and survival, many patients experience persistent pulmonary hypertension after pulmonary endarterectomy. The study objective was to calculate the pooled estimates of outcomes after pulmonary endarterectomy, including persistent pulmonary hypertension. METHODS: Meta-analyses were conducted on published studies reporting residual/persistent/recurrent pulmonary hypertension in 4868 patients with chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy. The rate of persistent pulmonary hypertension and change in mean pulmonary artery pressure, pulmonary vascular resistance, and 6-minute walk distance after pulmonary endarterectomy were outcomes of interest. RESULTS: Twenty-five percent of patients with chronic thromboembolic pulmonary hypertension were diagnosed with persistent pulmonary hypertension after pulmonary endarterectomy. Pulmonary endarterectomy reduced mean pulmonary artery pressure and pulmonary vascular resistance by approximately 21 mm Hg (standardized mean difference, 1.75; 95% confidence interval, -1.62 to 1.88; P < .00001) and 561 dyn.s/cm5 (standardized mean difference, 1.64; 95% confidence interval, -1.58 to 1.70; P < .00001), respectively. Conversely, 6-minute walk distance increased by 96 m (standardized mean difference, -0.83; 95% confidence interval, -0.91 to -0.76; P < .00001) after pulmonary endarterectomy. CONCLUSIONS: Pulmonary endarterectomy is the gold standard treatment for chronic thromboembolic pulmonary hypertension and provides immediate correction of hemodynamic parameters in most patients. However, in up to one quarter of operable cases, pulmonary hypertension persists after surgery. In those patients with persistent pulmonary hypertension, continued medical management with newer agents may be required to improve pulmonary hemodynamics and, therefore, patient outcomes.

1st Faculty of Medicine Charles University Prague Czech Republic; 2nd Department of Cardiovascular Surgery 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

2nd Department of Cardiovascular Surgery 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Critical Care and Cardiovascular Medical Center Kaohsiung Veterans General Hospital Kaohsiung Taiwan; College of Medicine National Yang Ming University Taipei Taiwan; Department of Physical Therapy Fooyin University Kaohsiung Taiwan

Department of Thoracic and Cardiovascular Surgery Research Institute Cleveland Clinic Cleveland Ohio

Pulmonary Hypertension Center 2nd Internal Clinic General University Hospital Prague 1st Faculty of Medicine Charles University Prague Czech Republic

Komentář v

J Thorac Cardiovasc Surg. 2018 Sep;156(3):1288-1289. doi: 10.1016/j.jtcvs.2018.05.072. PubMed

Citace poskytuje Crossref.org

Long-Term Treatment With Subcutaneous Treprostinil in Patients With Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension in the Multimodal Therapy Era (Data From CTREPH Study Open Label Extension)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic

Computed tomography angiographic parameters of pulmonary artery as prognostic factors of residual pulmonary hypertension after pulmonary endarterectomy

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile